Stockscreener 앱 받기
23.24
15.33%
3.09
전일 마감가:
$20.15
열려 있는:
$20.24
하루 거래량:
6.64M
Relative Volume:
2.48
시가총액:
$14.86B
수익:
$956.00K
순이익/손실:
$-196.68M
주가수익비율:
-96.83
EPS:
-0.24
순현금흐름:
$-113.02M
1주 성능:
+33.87%
1개월 성능:
+25.62%
6개월 성능:
+16.49%
1년 성능:
+476.67%
1일 변동 폭
$20.16
$23.31
1주일 범위
$15.55
$23.31
52주 변동 폭
$2.10
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
23.24 | 14.86B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Why Summit Therapeutics Inc. (SMMT) Soared Last Week? - Insider Monkey
3 Magnificent Stocks That Could Double or More by 2030 - Yahoo Finance
Summit Therapeutics spikes after co-CEO’s early warrants exercise - MSN
Summit Therapeutics: Not Pharmacyclics, Not Yet - Seeking Alpha
Why Summit Therapeutics Inc. (SMMT) Surged On Friday? - Insider Monkey
U.S. Indexes Moved Upward Friday; Summit Therapeutics Led Increases - Barron's
Summit co-CEO option exercise ‘quite bullish,’ says Cantor Fitzgerald - Yahoo Finance
Expert says Summit’s HARMONi-2 study could beat expectations, says Truist - Yahoo Finance
Summit Therapeutics (SMMT) Grants Stock Options to New Employees - GuruFocus
Summit Therapeutics (SMMT) Shows Resilient Cash Management Amid Challenges - GuruFocus
Why Summit Therapeutics Inc. (SMMT) Went Up On Thursday? - Insider Monkey
Truist maintains Buy on Summit Therapeutics, $35 target By Investing.com - Investing.com South Africa
10 Firms Buck Thursday’s Market Bloodbath - Insider Monkey
Summit Therapeutics (SMMT) Shares Surge After Insider Actions - GuruFocus
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets - MSN
Summit Therapeutics (SMMT) Sees Stock Surge Amid Early Warrant E - GuruFocus
Summit Therapeutics Shares Surge Amid Study Optimism - TipRanks
Summit Therapeutics (SMMT) Expected to Deliver Strong Results fr - GuruFocus
Summit Therapeutics (SMMT) Sees Bullish Surge as Co-CEO Exercise - GuruFocus
Summit Therapeutics stock gains on insider buy (SMMT:NASDAQ) - Seeking Alpha
Truist maintains Buy on Summit Therapeutics, $35 target - Investing.com
Cantor Fitzgerald maintains Overweight on Summit Therapeutics - Investing.com
Summit Therapeutics Co-CEOs Make Bold Stock Purchases! - TipRanks
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - Yahoo Finance
Optimistic Buy Rating for Summit Therapeutics Driven by Promising HARMONi-2 Trial and Favorable Regulatory Pathway in China - TipRanks
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Summit Therapeutics Inc.SMMT - MarketScreener
We Think Summit Therapeutics (NASDAQ:SMMT) Can Easily Afford To Drive Business Growth - Yahoo Finance
(SMMT) Technical Data - news.stocktradersdaily.com
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics Agrees to $127K Settlement in Wage Dispute - USA Herald
Summit Therapeutics Strengthens Team with Strategic Stock Options Worth $3.4M - Stock Titan
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Summit Therapeutics (SMMT) Surpasses Nvidia with High Hopes for Cancer Drug - GuruFocus
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months - Yahoo Finance
Chinese Biotech Eyes US Nod for Cancer Therapy Eluding Merck - Bloomberg.com
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today - Yahoo Finance
Virtu Financial LLC Cuts Holdings in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Summit Therapeutics: Major Upcoming Ivonescimab Data Catalyst May Not Be All It Seems (Rating Downgrade) - Seeking Alpha
Why Summit Therapeutics Stock Slipped Today - MSN
Summit Therapeutics (SMMT) Stock Movement Analysis - GuruFocus
Small cap wrap: Nano One Materials, EnWave, Summit Therapeutics... - Proactive Investors UK
Citigroup Upgrades Summit Therapeutics (BMV:SMMT) - Nasdaq
Summit Therapeutics stock rises on Citi upgrade (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics rises as lead asset makes Citi its latest bull - MSN
Summit Therapeutics upgraded ahead of lung cancer trial data readout - Proactive financial news
Citigroup Upgrades Summit Therapeutics (SMMT) - Nasdaq
S&P 500 Futures Decline in Premarket Trading; GameStop, Summit Therapeutics Lead - Barron's
Citigroup Upgrades Summit Therapeutics to Buy From Neutral, Adjusts Price Target to $35 From $23 - MarketScreener
Citi raises Summit Therapeutics rating to Buy, PT to $35 By Investing.com - Investing.com UK
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.37%
자본화:
|
볼륨(24시간):